Featured as an emerging technology and innovation in endovascular medicine, the presentation will highlight the potential of enVVe to address the significant unmet need in deep venous diseaseThe premier global forum for
Initial 10-patient stage of U.S. pivotal study of the first-in-class enVVe non-surgical replacement venous valve on track to begin before year endCash and investments of $18.5 million expected to fund operations into Q4
CEO-led series gives investors the story - straight talk, no B.S., no corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the next episode here
IRVINE, CA /
Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe® System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal studyAn estimated 3 million
New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the inaugural
Access the video webcast here
Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today
Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief
Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be
Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the
CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease MarketWatch the "What This Means" video here IRVINE, CA / ACCESS
New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market
- Live webcast on Wednesday, June 24th at 2:00 PM ET- Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO)
First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous ValveIDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3
